0001628280-23-027933.txt : 20230808 0001628280-23-027933.hdr.sgml : 20230808 20230808070508 ACCESSION NUMBER: 0001628280-23-027933 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230803 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Foghorn Therapeutics Inc. CENTRAL INDEX KEY: 0001822462 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39634 FILM NUMBER: 231149253 BUSINESS ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-586-3100 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 fhtx-20230803.htm 8-K fhtx-20230803
false000182246200018224622023-08-032023-08-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
________________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2023
________________________________________________________________________________________________
Foghorn Therapeutics Inc.
(Exact name of registrant as specified in its charter)
________________________________________________________________________________________________
Delaware 001-39634 47-5271393
(State or other jurisdiction of incorporation) 
(Commission
File Number)
 (IRS Employer Identification No.)
500 Technology Square, Ste 700
Cambridge,
MA
02139
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number, including area code): (617) 586-3100
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Securities registered pursuant to Section 12(b) of the Act:  
Title of each class 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share FHTX The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 8.01     Other Information

On August 8, 2023, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing that Samuel Agresta, M.D., will step down from his position as Chief Medical Officer of the Company effective as of September 11, 2023. Following his resignation, Dr. Agresta will serve as a consultant to the Company through early January 2024.

The Company also announced that Alfonso Quintás-Cardama, M.D., has been appointed to serve as the Company’s Chief Medical Officer, effective as of September 11, 2023.

Dr. Quintás-Cardama previously served as Chief Medical Officer of TCR2 Therapeutics Inc., a position he held since 2017. Prior to that, he was the Clinical Development Head of the Cell & Gene Therapies Unit at GlaxoSmithKline PLC in 2017. Between 2014 and 2016, Dr. Quintás-Cardama served as Global Clinical Leader, Cell & Gene Therapy, at Novartis AG and was an Assistant Professor in the Department of Leukemia at the University of Texas, MD Anderson Cancer Center from 2009 to 2014. Dr. Quintás-Cardama received his M.D. from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine of the Albert Einstein College of Medicine, and a hematology and oncology fellowship and a leukemia fellowship at the University of Texas, MD Anderson Cancer Center.

A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
FOGHORN THERAPEUTICS INC.
 
By: /s/ Allan Reine
 Allan Reine, M.D.
 Chief Financial Officer
Date: August 8, 2023

EX-99.1 2 ex9912023-08x08xpressrelea.htm EX-99.1 Document
Exhibit 99.1
Foghorn Therapeutics Announces Chief Medical Officer Succession
CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE) -- August 8, 2023 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced that Alfonso Quintás-Cardama, M.D., will join the company as Chief Medical Officer, on September 11, 2023. Foghorn’s current Chief Medical Officer, Sam Agresta, M.D., will simultaneously retire from the company on September 11, 2023, and will provide consulting services through early January 2024.

“I want to thank Sam for his leadership and many contributions to Foghorn over the past four years. He joined the company at a critical time and built our clinical team which advanced our first programs to the clinic,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “Sam has been a valued partner to me and the entire organization, and his unwavering focus on our mission to serve patients has been inspiring not just to me, but to all of us.”
Gottschalk continued, “We are excited to welcome Alfonso to the Foghorn team. Alfonso’s experience and expertise in oncology and as a leukemia expert will be integral to our plans as we continue to advance our pipeline and develop medicines for patients.”
Dr. Quintás-Cardama most recently was the Chief Medical Officer at TCR2 since 2017, where he led the development of the company’s cell therapy platform. Dr. Quintás-Cardama’s prior experience includes a role as the head of clinical development for cell therapies at GSK, where he was instrumental in building GSK’s cell therapies unit, and as the global clinical leader at Novartis from 2014 to 2016, where he led the development of tisagenlecleucel (Kymriah™, CTL019), the first FDA-approved CAR-T cell therapy. Dr. Quintás-Cardama was previously a faculty member of the Department of Leukemia at MD Anderson Cancer Center from 2009 to 2014, where he developed multiple FDA-approved targeted agents for the treatment of myeloid malignancies.
“As a leader in understanding and drugging chromatin biology, Foghorn is uniquely positioned to develop the next class of cancer medicines,” said Dr. Quintás-Cardama. “I am excited to join Foghorn given the company’s broad pipeline coupled with a platform that has enabled the drugging of some of the most compelling targets in cancer. I am looking forward to being part of the Foghorn journey as the company continues to address unmet needs in cancer and brings potential therapies to people who need it the most.”
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at


www.foghorntx.com for more information on the company, and follow us on X (formally Twitter) and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, including its Phase 1 study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory AML patients, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Contact:
Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com
Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com

 EX-101.SCH 3 fhtx-20230803.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 fhtx-20230803_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Name of each exchange on which registered Security Exchange Name Title of each class Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol(s) Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 fhtx-20230803_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 03, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 03, 2023
Entity Registrant Name Foghorn Therapeutics Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39634
Entity Tax Identification Number 47-5271393
Entity Address, Address Line One 500 Technology Square, Ste 700
City Area Code 617
Local Phone Number 586-3100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common Stock, $0.0001 par value per share
Trading Symbol(s) FHTX
Name of each exchange on which registered NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Flag false
Entity Central Index Key 0001822462
Entity Address, City or Town MA
Entity Address, City or Town Cambridge,
Entity Address, Postal Zip Code 02139
XML 7 fhtx-20230803_htm.xml IDEA: XBRL DOCUMENT 0001822462 2023-08-03 2023-08-03 false 0001822462 8-K 2023-08-03 Foghorn Therapeutics Inc. DE 001-39634 47-5271393 500 Technology Square, Ste 700 Cambridge, MA 02139 617 586-3100 false false false false Common Stock, $0.0001 par value per share FHTX NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.foghorntx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports fhtx-20230803.htm ex9912023-08x08xpressrelea.htm fhtx-20230803.xsd fhtx-20230803_lab.xml fhtx-20230803_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "fhtx-20230803.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "fhtx-20230803.htm" ] }, "labelLink": { "local": [ "fhtx-20230803_lab.xml" ] }, "presentationLink": { "local": [ "fhtx-20230803_pre.xml" ] }, "schema": { "local": [ "fhtx-20230803.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "fhtx", "nsuri": "http://www.foghorntx.com/20230803", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20230803.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.foghorntx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20230803.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol(s)" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.foghorntx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001628280-23-027933-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-027933-xbrl.zip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

Y'CQ9P%#??/T?K7,3ZEBU1_+6!?G)/(@\TB :HM;($55#^&&HTD M#E%;92"<<5W)O[(^C(T9]RM*?]77/4/93$AF&GG$:,.HN!& M(,T53'XB,$]81A4UTV&Q9WL8&3-N2DXDZV1PO%L]4?(<#IP# X>'!R97-S